Affinage

SART3

Spliceosome associated factor 3, U4/U6 recycling protein · UniProt Q15020

Length
963 aa
Mass
109.9 kDa
Annotated
2026-06-10
100 papers in source corpus 16 papers cited in narrative 16 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SART3 is a nuclear RNA-binding protein that functions as the human ortholog of yeast Prp24 and serves as the U4/U6 snRNP recycling factor that regenerates spliceosomal di-snRNPs after each round of splicing (PMID:12032085). Its bipartite architecture couples C-terminal RNA recognition motifs (RRMs), which bind a specific internal region of U6 snRNA, to an N-terminal TPR/HAT repeat domain that mediates protein–protein contacts, and both are required for recycling activity (PMID:12032085, PMID:15314151). The TPR domain engages the U4/U6-specific 90K protein, while the conserved C-terminus is bound by LSm2-8 proteins that recruit SART3 to U6 snRNA, integrating it into the snRNP remodeling machinery (PMID:15314151, PMID:18567812). SART3 concentrates in Cajal bodies via its HAT domain and directs U6 snRNP localization there for recycling, and more broadly monitors tri-snRNP assembly by sequestering incomplete snRNP intermediates onto the coilin scaffold to maintain snRNP homeostasis (PMID:12578909, PMID:25600876); its essential recycling role is confirmed in vivo, where loss disrupts U4/U6 snRNPs and causes organ defects (PMID:17416673). The crystal structure of the HAT domain shows it forms a dimer through HAT-C and recruits the deubiquitinases USP4 and USP15, whose nuclear import and catalytic activity depend on the SART3 nuclear localization signal (PMID:27060135). Beyond splicing, SART3 acts as a histone chaperone that presents evicted mono-ubiquitinated H2B to USP15 for deubiquitination (PMID:24526689), scaffolds the Polη/RAD18 complex to promote PCNA monoubiquitination and translesion synthesis after UV damage in an RNA-binding-independent manner (PMID:29590477), potentiates HIV-1 Tat-mediated LTR transactivation through direct Tat interaction in nuclear speckles (PMID:11959860), and promotes miR-34a biogenesis through RRM-mediated pre-miR-34a binding to enforce a CDK4/6-dependent G1 arrest (PMID:31619517). A SART3 missense mutation was linked to disseminated superficial actinic porokeratosis in a single family by linkage analysis (PMID:15840095).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2001 High

    Established SART3 as a participant in splicing regulation by identifying a direct interaction with the splicing factor RNPS1 that redirects SART3 to nuclear speckles and modulates alternative 3' splice site choice.

    Evidence Yeast two-hybrid, pull-down, Co-IP, and minigene splicing assay

    PMID:11477570

    Open questions at the time
    • Does not define the snRNP-level mechanism
    • Physiological pre-mRNA targets not identified
  2. 2002 High

    Defined the core molecular function of SART3 as the U4/U6 snRNP recycling factor, the human Prp24 ortholog, that binds U6 snRNA and reassembles U4/U6 di-snRNPs after each splicing cycle.

    Evidence RNA immunoprecipitation, in vitro U6 binding, and in vitro recycling reconstitution

    PMID:12032085

    Open questions at the time
    • Protein partners during recycling not yet mapped
    • In vivo requirement not yet tested
  3. 2002 High

    Revealed a non-splicing role by showing direct Tat binding and potentiation of HIV-1 LTR transactivation, expanding SART3 function into transcriptional control in nuclear speckles.

    Evidence Reciprocal Co-IP with mutagenesis, CAT reporter, virus production, and microscopy

    PMID:11959860

    Open questions at the time
    • Mechanism by which SART3 enhances Tat function unresolved
    • Relationship to its splicing role unclear
  4. 2003 High

    Localized SART3 function to Cajal bodies, showing the HAT domain is necessary and sufficient for CB targeting and is required to deliver U6 snRNP there for recycling.

    Evidence GFP truncation mutants, dominant-negative overexpression, alpha-amanitin treatment

    PMID:12578909

    Open questions at the time
    • Molecular basis of HAT-mediated CB targeting not defined
    • Link between CB localization and recycling kinetics unquantified
  5. 2004 High

    Dissected the domain requirements for recycling, showing both RRMs and the TPR domain are needed and that the TPR domain contacts the U4/U6-specific 90K protein.

    Evidence In vitro recycling with deletion mutants, RNA binding, yeast two-hybrid

    PMID:15314151

    Open questions at the time
    • Structure of the SART3–90K interface not determined
    • Order of RNA versus protein contacts during recycling unknown
  6. 2004 Medium

    Identified a transcriptional repressor function, showing NR-box-dependent binding to the androgen receptor that suppresses AR-driven transcription and PSA expression.

    Evidence Co-IP with motif mutant, reporter assay, siRNA knockdown, EMSA

    PMID:15031286

    Open questions at the time
    • In vivo relevance to prostate biology not established
    • Single-lab study
  7. 2007 High

    Validated the recycling function in vivo, showing that loss of SART3 in zebrafish disrupts U4/U6 snRNPs and causes organ defects with compensatory upregulation of spliceosome components.

    Evidence Zebrafish loss-of-function mutant, snRNP fractionation, expression profiling

    PMID:17416673

    Open questions at the time
    • Tissue-specific sensitivity to recycling loss unexplained
    • Compensatory network regulators not identified
  8. 2008 High

    Clarified how SART3 is recruited to U6, showing LSm2-8 proteins bind the conserved C-terminus and act synergistically with SART3, with the U6 3'-cyclic phosphate biasing toward LSm over La binding.

    Evidence In vitro binding assays with recombinant proteins and synthetic U6 variants

    PMID:18567812

    Open questions at the time
    • Temporal coordination of LSm and SART3 loading in cells unresolved
  9. 2011 Medium

    Extended SART3 into hematopoiesis, showing dose-dependent control of progenitor expansion, survival, and cycling via reciprocal transcriptional regulation with CMYC and control of GATA2.

    Evidence Transgenic and haploinsufficient mouse models, colony assays, cell cycle and expression analysis

    PMID:21447833

    Open questions at the time
    • Direct versus indirect transcriptional mechanism not resolved
    • Connection to splicing function unclear
  10. 2014 High

    Defined a histone chaperone role, showing SART3 directly binds USP15 and presents mono-ubiquitinated free histone H2B for deubiquitination, linking SART3 to chromatin/transcription-coupled histone turnover.

    Evidence Affinity purification with ubH2B mimic, Co-IP, in vitro deubiquitination of free histones versus nucleosomes

    PMID:24526689

    Open questions at the time
    • In vivo H2B deubiquitination dependence on SART3 not quantified
    • Why nucleosomal ubH2B is not a substrate unexplained
  11. 2016 High

    Provided structural and mechanistic basis for DUB regulation, showing the HAT domain dimerizes and recruits USP4/USP15, and that the SART3 NLS drives their nuclear import and catalytic activity.

    Evidence X-ray crystallography of HAT and HAT–USP4 complex, affinity measurements, NLS deletion and DUB activity assays

    PMID:27060135

    Open questions at the time
    • Substrate specificity of nuclear USP4/USP15 once imported not addressed
  12. 2018 High

    Established an RNA-independent DNA damage tolerance function, showing C-terminal-mediated scaffolding of Polη/RAD18, promotion of PCNA monoubiquitination, and protection against UV-induced mutagenesis.

    Evidence Co-IP with domain mapping, siRNA knockdown with UV survival/mutation assays, foci imaging, PCNA ubiquitination assay

    PMID:29590477

    Open questions at the time
    • How a splicing factor is recruited to stalled forks unknown
    • Relationship between dimerization and TLS scaffolding unresolved
  13. 2019 Medium

    Linked SART3 to miRNA biogenesis, showing RRM-dependent specific binding to pre-miR-34a that raises mature miR-34a, downregulates CDK4/6, and arrests cells in G1.

    Evidence Pull-down identification, in vitro RNA binding with RRM mutants, miRNA quantification, cell cycle analysis

    PMID:31619517

    Open questions at the time
    • Step in miR-34a processing affected not pinpointed
    • Single-lab study
  14. 2020 Medium

    Showed that a stress-induced lncRNA, LASTR, tunes SART3 association with U4/U6 snRNPs to maintain splicing efficiency and cancer cell fitness, adding an RNA-based regulatory layer to recycling.

    Evidence Mass spectrometry, RNA-IP, intron retention RNA-seq, LASTR depletion viability assay

    PMID:31956895

    Open questions at the time
    • Direct versus indirect modulation of SART3 by LASTR not separated
    • Single-lab study

Open questions

Synthesis pass · forward-looking unresolved questions
  • How SART3's distinct activities — snRNP recycling, histone deubiquitination, translesion synthesis, transcriptional and miRNA regulation — are coordinated within the nucleus, and which are physiologically dominant, remains unresolved.
  • No unifying model linking the multiple functions
  • Mechanism of the DSAP disease mutation not functionally tested
  • Context-specific partitioning between roles unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 4 GO:0060090 molecular adaptor activity 4 GO:0098772 molecular function regulator activity 2 GO:0140110 transcription regulator activity 2 GO:0042393 histone binding 1
Localization
GO:0005654 nucleoplasm 3 GO:0005634 nucleus 2
Pathway
R-HSA-8953854 Metabolism of RNA 5 R-HSA-74160 Gene expression (Transcription) 2 R-HSA-4839726 Chromatin organization 1 R-HSA-73894 DNA Repair 1
Partners
COILINPOLHPRPF3RAD18RNPS1TATUSP15USP4
Complex memberships
Cajal bodyU4/U6 di-snRNP

Evidence

Reading pass · 16 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 SART3/p110 (human ortholog of yeast Prp24) associates specifically with U6 and U4/U6 snRNPs but not with U4/U5/U6 tri-snRNPs or spliceosomes. Recombinant p110 binds U6 snRNA in vitro requiring an internal U6 region, and p110 functions in the reassembly of U4/U6 snRNP in an in vitro recycling assay, establishing its role as a U4/U6 snRNP recycling factor. Its domain structure comprises an N-terminal region with seven tetratricopeptide repeat (TPR) domains and C-terminal RNA recognition motifs (RRMs). RNA immunoprecipitation, in vitro RNA binding assay, in vitro U4/U6 snRNP recycling assay, database/domain analysis The EMBO journal High 12032085
2003 SART3/p110 is enriched in Cajal bodies (CBs) but not in gems or residual CBs lacking coilin. Its N-terminal HAT domain is necessary and sufficient for targeting to CBs. Overexpression of truncation mutants containing the HAT domain had dominant-negative effects on U6 snRNP localization to CBs, indicating SART3 plays a role in targeting U6 snRNP to CBs. CB localization was reduced by the transcription inhibitor alpha-amanitin, linking CB accumulation to active transcription/splicing. Fluorescence microscopy with GFP-tagged truncation mutants, dominant-negative overexpression, alpha-amanitin treatment, immunofluorescence The Journal of cell biology High 12578909
2004 SART3/p110 U4/U6 snRNP recycling activity requires both its RRM domains and its TPR domain, but not the highly conserved C-terminal 10 amino acids. The two RRMs with flanking regions are sufficient for U6-specific RNA binding. The TPR domain interacts with the U4/U6-specific 90K protein (via residues 416-550 of 90K) in yeast two-hybrid assays, suggesting the TPR domain mediates protein-protein interactions during spliceosome recycling. In vitro recycling assay with deletion mutants, in vitro RNA binding, yeast two-hybrid Molecular and cellular biology High 15314151
2007 Zebrafish earl grey (egy) mutation maps to the p110/SART3 gene and causes thymus hypoplasia and other organ defects. U4/U6 snRNPs were disrupted in egy mutant embryos, confirming that p110/SART3 is essential for U4/U6 snRNP recycling in vivo. Loss of p110/SART3 triggered coordinated upregulation of a network of spliceosome cycle components, providing a compensatory mechanism for the recycling defect. Genetic mapping, zebrafish loss-of-function mutant analysis, snRNP fractionation, expression profiling Proceedings of the National Academy of Sciences of the United States of America High 17416673
2008 The 3'-cyclic phosphate on U6 snRNA enhances binding of LSm2-8 proteins to U6 snRNA and reduces La protein binding, facilitating RNP remodeling. LSm2-8 proteins recruit p110/SART3 to U6 snRNA via direct interaction with the highly conserved C-terminal region of p110, demonstrating synergistic binding of LSm proteins and p110 to U6 snRNA. In vitro binding assays with purified/recombinant proteins and synthetic U6 variants, gel-shift and pull-down assays RNA (New York, N.Y.) High 18567812
2001 SART3 interacts physically with the pre-mRNA splicing factor RNPS1 through the N-terminal domains of RNPS1, as confirmed by in vitro pull-down and co-immunoprecipitation. Co-transfection of both genes redistributes SART3 from diffuse nucleoplasmic to nuclear speckled regions co-localizing with RNPS1. In cooperation with RNPS1, SART3 stimulates proximal alternative 3' splicing of a calcitonin-DHFR chimeric minigene pre-mRNA. Yeast two-hybrid, in vitro pull-down, co-immunoprecipitation, immunofluorescence, minigene splicing assay International journal of cancer High 11477570
2002 SART3/TIP110 (Tip110) interacts directly with HIV-1 Tat protein in vivo, confirmed by co-immunoprecipitation and Western blotting combined with mutagenesis. Tip110 strongly potentiates Tat-mediated HIV-1 LTR promoter transactivation and HIV-1 virus production; knock-down of Tip110 inhibits HIV-1 production. Tip110 localizes exclusively to the nucleus in nuclear speckle structures overlapping with cyclin T and CDK9. Co-immunoprecipitation, Western blot, mutagenesis, CAT reporter assay, siRNA knockdown, digital fluorescence microscopy The Journal of biological chemistry High 11959860
2014 SART3 has histone chaperone activity and directly associates with the deubiquitinase Usp15 in the nucleus. SART3 enhances Usp15 binding to mono-ubiquitinated H2B (ubH2B) and facilitates deubiquitination of ubH2B in free histones (but not in nucleosomes), suggesting SART3 recruits ubH2B evicted during transcription for deubiquitination. SART3 also indirectly associates with the ubH2B E3 ligase RNF20/RNF40. Affinity purification with non-hydrolyzable ubH2B mimic, co-immunoprecipitation, in vitro deubiquitination assay with nucleosomes and free histones The Journal of biological chemistry High 24526689
2015 SART3 is required for the accumulation of incomplete spliceosomal snRNP intermediates in Cajal bodies (CBs). Depletion of SART3 prevents both the induction of CB formation (triggered by imbalanced snRNP assembly) and the tethering of incomplete snRNPs to coilin (CB scaffolding protein), indicating SART3 monitors tri-snRNP assembly and sequesters incomplete particles in CBs to maintain homeostatic balance of mature snRNPs. siRNA depletion, immunofluorescence microscopy, co-immunoprecipitation with coilin Cell reports High 25600876
2016 Crystal structure of the SART3 HAT (half-a-tetratricopeptide) repeat domain alone and in complex with the DUSP-UBL domains of USP4 was determined. The 12 HAT repeats form two sub-domains (HAT-N and HAT-C); HAT-C mediates dimerization; USP4 binds at the opposite surface of the HAT-C dimer interface via the beta-structured linker between DUSP and UBL. Binding affinities of USP4 and USP15 to SART3 are 0.9 μM and 0.2 μM respectively. The SART3 nuclear localization signal (NLS) forms bipartite interaction with importin-α; deletion of the NLS prevents nuclear entry of USP4 and USP15 and abrogates USP4 deubiquitinase activity. X-ray crystallography, binding affinity measurements (SPR/ITC implied), NLS deletion mutants, nuclear localization assay, deubiquitinase activity assay Nucleic acids research High 27060135
2018 SART3 interacts with DNA polymerase η (Polη) and RAD18 via its C-terminus, and can form homodimers that promote the Polη/RAD18 interaction and PCNA monoubiquitination after UV exposure. Depletion of SART3 impairs UV-induced ssDNA generation and RPA focus formation, reduces Polη recruitment to stalled replication forks, and increases mutation frequency and UV hypersensitivity. This function is RNA binding-independent. Affinity purification/co-IP, deletion mapping (C-terminus), siRNA knockdown with UV survival/mutation frequency assay, immunofluorescence for RPA and Polη foci, PCNA ubiquitination assay Nucleic acids research High 29590477
2019 SART3 binds pre-miR-34a with higher specificity than a negative-control pre-miRNA via its RNA recognition motifs (RRMs). SART3 overexpression increases mature miR-34a levels, downregulates miR-34a target genes CDK4/6, and causes G1 cell cycle arrest in non-small-cell lung cancer cells. Proteomics/pull-down identification, in vitro RNA binding with RRM mutants, overexpression with miRNA quantification, CDK4/6 Western blot, flow cytometry cell cycle analysis The Journal of biological chemistry Medium 31619517
2020 The stress-induced lncRNA LASTR interacts with SART3 (identified by mass spectrometry) and promotes splicing efficiency by controlling SART3 association with U4 and U6 snRNPs during spliceosome recycling; LASTR depletion causes intron retention and decreases cancer cell fitness. Mass spectrometry-based affinity purification, RNA immunoprecipitation, intron retention analysis (RNA-seq), LASTR depletion with cell viability assay Nucleic acids research Medium 31956895
2011 TIP110/SART3 is expressed in human CD34+ hematopoietic stem/progenitor cells and decreases with differentiation. Using TIP110 transgenic and haploinsufficient mice, increased TIP110 enhanced hematopoietic progenitor cell (HPC) numbers, survival, and cycling, while decreased TIP110 had opposite effects. TIP110 regulates CMYC and GATA2 expression at the transcriptional level, and TIP110 and CMYC reciprocally regulate each other's expression. Transgenic and haploinsufficient mouse models, colony-forming assays, cell cycle analysis, RT-PCR/Western blot for CMYC and GATA2 Blood Medium 21447833
2004 Tip110/SART3 binds to androgen receptor (AR) in an NR box (LXXLL motif)-dependent manner and suppresses AR transcriptional activation of androgen-responsive element (ARE)-driven reporters. Knockdown of Tip110 augments AR transcriptional activation. Tip110 overexpression blocks PSA gene expression and prevents AR–ARE complex formation. Co-immunoprecipitation, reporter gene assay, siRNA knockdown, EMSA (AR-ARE complex), Western blot The Journal of biological chemistry Medium 15031286
2005 A Val591Met missense mutation in SART3 was identified by linkage analysis and sequencing in all affected individuals of a six-generation Chinese family with disseminated superficial actinic porokeratosis (DSAP), mapping to chromosome 12q24.1-24.2, suggesting SART3 is a candidate disease gene for this autosomal dominant skin disorder. Genome-wide linkage analysis, haplotype analysis, Sanger sequencing The British journal of dermatology Low 15840095

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1998 Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Molecular and cellular biology 431 9488453
1992 I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family. Cell 279 1339305
2006 Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. Journal of immunology (Baltimore, Md. : 1950) 263 17082571
2010 The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nature chemical biology 228 20081827
2002 Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. The Journal of cell biology 210 12507995
1991 The SH2 and SH3 domains of pp60src direct stable association with tyrosine phosphorylated proteins p130 and p110. The EMBO journal 210 1710979
2007 Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proceedings of the National Academy of Sciences of the United States of America 184 17470792
1998 Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. The Journal of biological chemistry 179 9507010
2010 PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 161 20505158
2010 PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arteriosclerosis, thrombosis, and vascular biology 153 20237330
1998 The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha. The Journal of biological chemistry 150 9748276
2011 Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PloS one 135 21984893
2007 CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer. Blood 126 18006698
2002 Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. The Journal of biological chemistry 123 12145276
1995 A phosphatidylinositol (PI) kinase gene family in Dictyostelium discoideum: biological roles of putative mammalian p110 and yeast Vps34p PI 3-kinase homologs during growth and development. Molecular and cellular biology 113 7565716
2002 p110, a novel human U6 snRNP protein and U4/U6 snRNP recycling factor. The EMBO journal 112 12032085
2013 FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade. Nature cell biology 109 23604317
2009 Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. Journal of immunology (Baltimore, Md. : 1950) 109 19843950
2008 Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. Journal of immunology (Baltimore, Md. : 1950) 102 18250464
2002 Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. The Journal of biological chemistry 102 11956182
1999 Src-family tyrosine kinases in activation of ERK-1 and p85/p110-phosphatidylinositol 3-kinase by G/CCKB receptors. The Journal of biological chemistry 101 10400698
1998 NRP/B, a novel nuclear matrix protein, associates with p110(RB) and is involved in neuronal differentiation. The Journal of cell biology 94 9566959
2003 Targeting of U4/U6 small nuclear RNP assembly factor SART3/p110 to Cajal bodies. The Journal of cell biology 92 12578909
1994 Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. Genomics 91 7713498
2008 The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. The Journal of experimental medicine 89 18809712
2021 Decoupling expression and editing preferences of ADAR1 p150 and p110 isoforms. Proceedings of the National Academy of Sciences of the United States of America 85 33723056
2002 Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Laboratory investigation; a journal of technical methods and pathology 84 12218074
1997 Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). The Journal of biological chemistry 84 9162067
2014 The U4/U6 recycling factor SART3 has histone chaperone activity and associates with USP15 to regulate H2B deubiquitination. The Journal of biological chemistry 83 24526689
2008 Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer cell 83 18691552
1994 Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits. Molecular and cellular biology 83 8264609
1996 Wortmannin inhibits mitogen-activated protein kinase activation by platelet-activating factor through a mechanism independent of p85/p110-type phosphatidylinositol 3-kinase. The Journal of biological chemistry 78 8662643
2009 Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction. Circulation 77 19597047
1995 Phosphatidylinositol 3,4,5-trisphosphate is a substrate for the 75 kDa inositol polyphosphate 5-phosphatase and a novel 5-phosphatase which forms a complex with the p85/p110 form of phosphoinositide 3-kinase. The EMBO journal 76 7556092
2004 Failure to proliferate and mitotic arrest of CDK11(p110/p58)-null mutant mice at the blastocyst stage of embryonic cell development. Molecular and cellular biology 75 15060143
2001 PITSLRE p110 protein kinases associate with transcription complexes and affect their activity. The Journal of biological chemistry 75 11709559
2020 Class IA PI3K regulatory subunits: p110-independent roles and structures. Biochemical Society transactions 72 32677674
2010 The class IA phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy. The Journal of cell biology 72 21059846
2007 PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein. Biochemical and biophysical research communications 72 17475214
1997 Specific activation of p85-p110 phosphatidylinositol 3'-kinase stimulates DNA synthesis by ras- and p70 S6 kinase-dependent pathways. Molecular and cellular biology 71 8972205
2006 Mycoplasma genitalium P140 and P110 cytadhesins are reciprocally stabilized and required for cell adhesion and terminal-organelle development. Journal of bacteriology 69 17028283
2000 The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. Journal of cell science 69 10633072
2007 Network of coregulated spliceosome components revealed by zebrafish mutant in recycling factor p110. Proceedings of the National Academy of Sciences of the United States of America 66 17416673
2011 CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert opinion on investigational drugs 64 22112004
2006 Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. Journal of cellular physiology 64 16775835
2009 Phosphoinositide 3-kinase p110 beta regulates integrin alpha IIb beta 3 avidity and the cellular transmission of contractile forces. The Journal of biological chemistry 62 19940148
2008 Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. Journal of immunology (Baltimore, Md. : 1950) 61 18250413
2015 SART3-Dependent Accumulation of Incomplete Spliceosomal snRNPs in Cajal Bodies. Cell reports 60 25600876
2006 The p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase. Molecular and cellular biology 57 16508018
2003 Activated G alpha q inhibits p110 alpha phosphatidylinositol 3-kinase and Akt. The Journal of biological chemistry 56 12704201
2000 Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. International journal of cancer 56 11058882
1994 Direct association of p110 beta phosphatidylinositol 3-kinase with p85 is mediated by an N-terminal fragment of p110 beta. Molecular and cellular biology 55 8139559
2015 Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth. Scientific reports 54 25990212
2016 Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk. Nature communications 52 27255951
2009 Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation. Molecular immunology 52 19362372
2009 p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin. The Journal of biological chemistry 51 19635798
2002 HIV-1 Tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear Tat-interacting protein of 110 kDa, Tip110. The Journal of biological chemistry 51 11959860
2000 Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. Journal of immunotherapy (Hagerstown, Md. : 1997) 51 11001544
2000 Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. The American journal of pathology 51 11073819
2009 PI3K p110 alpha and p110 beta have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts. Cell death and differentiation 49 19834495
2007 Genome-wide location analysis and expression studies reveal a role for p110 CUX1 in the activation of DNA replication genes. Nucleic acids research 49 18003658
1997 Biochemical characterization of mammalian translation initiation factor 3 (eIF3). Molecular cloning reveals that p110 subunit is the mammalian homologue of Saccharomyces cerevisiae protein Prt1. The Journal of biological chemistry 48 9388245
2008 3'-cyclic phosphorylation of U6 snRNA leads to recruitment of recycling factor p110 through LSm proteins. RNA (New York, N.Y.) 47 18567812
1998 Phosphorylation of PITSLRE p110 isoforms accompanies their processing by caspases during Fas-mediated cell death. The Journal of biological chemistry 47 9632733
2008 Critical roles of the p110 beta subtype of phosphoinositide 3-kinase in lipopolysaccharide-induced Akt activation and negative regulation of nitrite production in RAW 264.7 cells. Journal of immunology (Baltimore, Md. : 1950) 46 18250410
2018 Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. Proceedings of the National Academy of Sciences of the United States of America 45 30442661
2005 Cellular retinol-binding protein-I inhibits PI3K/Akt signaling through a retinoic acid receptor-dependent mechanism that regulates p85-p110 heterodimerization. Oncogene 45 15608670
2011 Ablation of PI3K p110-α prevents high-fat diet-induced liver steatosis. Diabetes 44 21464441
2012 Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 43 22711705
2020 Stress-induced lncRNA LASTR fosters cancer cell fitness by regulating the activity of the U4/U6 recycling factor SART3. Nucleic acids research 42 31956895
2020 Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110. Cancer letters 42 33309857
2009 Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cancer research 42 19738070
2015 PTBP1 induces ADAR1 p110 isoform expression through IRES-like dependent translation control and influences cell proliferation in gliomas. Cellular and molecular life sciences : CMLS 41 26047657
2014 PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2. Journal of neurochemistry 40 24645666
2008 p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes. Molecular and cellular biology 37 18347061
2007 In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN. Cancer research 37 17942903
2012 Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene 36 22751112
2005 A mutation in SART3 gene in a Chinese pedigree with disseminated superficial actinic porokeratosis. The British journal of dermatology 36 15840095
2004 Human U4/U6 snRNP recycling factor p110: mutational analysis reveals the function of the tetratricopeptide repeat domain in recycling. Molecular and cellular biology 36 15314151
2018 Mycoplasma genitalium adhesin P110 binds sialic-acid human receptors. Nature communications 35 30367053
2001 p110-related PI 3-kinases regulate phagosome-phagosome fusion and phagosomal pH through a PKB/Akt dependent pathway in Dictyostelium. Journal of cell science 35 11256995
1994 Biochemical characterization of the free catalytic p110 alpha and the complexed heterodimeric p110 alpha.p85 alpha forms of the mammalian phosphatidylinositol 3-kinase. The Journal of biological chemistry 34 7929193
2006 Class IA phosphatidylinositide 3-kinases, rather than p110 gamma, regulate formyl-methionyl-leucyl-phenylalanine-stimulated chemotaxis and superoxide production in differentiated neutrophil-like PLB-985 cells. Journal of immunology (Baltimore, Md. : 1950) 33 16751409
2001 Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 32 11398844
2001 Phosphatidylinositol 3-kinase p85 adaptor function in T-cells. Co-stimulation and regulation of cytokine transcription independent of associated p110. The Journal of biological chemistry 32 11679587
2016 Structural basis for recruiting and shuttling of the spliceosomal deubiquitinase USP4 by SART3. Nucleic acids research 31 27060135
2019 The RNA-binding protein SART3 promotes miR-34a biogenesis and G1 cell cycle arrest in lung cancer cells. The Journal of biological chemistry 30 31619517
2012 Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 23172887
2010 The p110 delta isoform of phosphatidylinositol 3-kinase controls the quality of secondary anti-Leishmania immunity by regulating expansion and effector function of memory T cell subsets. Journal of immunology (Baltimore, Md. : 1950) 30 20154209
2007 Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells. The Journal of pathology 30 17427168
2007 Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins. The Biochemical journal 30 17680774
2001 Binding of a SART3 tumor-rejection antigen to a pre-mRNA splicing factor RNPS1: a possible regulation of splicing by a complex formation. International journal of cancer 30 11477570
1995 Expression of mdr1/P-glycoprotein and p110 in neuroblastoma. The Journal of pathology 30 7891222
2018 RNA-splicing factor SART3 regulates translesion DNA synthesis. Nucleic acids research 29 29590477
2011 TIP110/p110nrb/SART3/p110 regulation of hematopoiesis through CMYC. Blood 29 21447833
2004 Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. The Journal of biological chemistry 29 15031286
2013 The P110 subunit of PI3-K is a therapeutic target of acacetin in skin cancer. Carcinogenesis 27 23913940
2012 Tip110 maintains expression of pluripotent factors in and pluripotency of human embryonic stem cells. Stem cells and development 27 22132941
2006 ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia. American journal of physiology. Heart and circulatory physiology 27 16517941
1998 The p85 and p110 subunits of phosphatidylinositol 3-kinase-alpha are substrates, in vitro, for a constitutively associated protein tyrosine kinase in platelets. Blood 27 9446654

Missed literature

Know a paper Affinage missed for SART3? Flag it for the maintainers and the community.

No submissions yet.